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A B S T R A C T
Background: The number of diagnostic assays for the detection of herpes simplex virus type 1 (HSV-1) antibodies
has increased over the years. However, their performance characteristics could vary among global populations.
Objective: To investigate performance of two commercial ELISA kits, HerpeSelect® 1 ELISA and Euroimmun Anti-
HSV-1 (gC1) ELISA (IgG); and two commercial immunoblot (IB)/Western blot (WB) assays, HerpeSelect® 1 and 2
Immunoblot IgG, and Euroimmun Anti-HSV-1/HSV-2 gG2 Euroline-WB (IgG/IgM); in detecting HSV-1 anti-
bodies in a Middle East and North Africa (MENA) population.
Study design: Blood specimens were collected from blood donors in Doha, Qatar, June 2013–2016. Twenty
specimens were randomly selected from 10 MENA nationalities (Egypt, Iran, Jordan, Lebanon, Pakistan,
Palestine, Qatar, Sudan, Syria, and Yemen; total= 200), and tested for HSV-1 antibodies.
Results: Across all six comparisons between assays, positive percent agreement ranged between 95.7% (95% CI:
91.4–98.3%) and 100.0% (95% CI: 97.8–100.0%). Negative percent agreement ranged between 86.2% (95% CI:
68.3-96.1%) and 96.2% (95% CI: 80.4–99.9%). Overall percent agreement ranged between 95.7% (95% CI:
91.7–97.8%) and 99.4% (95% CI: 96.7–99.9%). Cohen’s kappa statistic ranged between 0.84 (95% CI:
0.73–0.95) and 0.98 (95% CI: 0.93–1.00). Compared against IB/WB, HerpeSelect® and Euroimmun had sensi-
tivities and specificities> 96% and>86%, respectively. Positive and negative predictive values were>97%
and>83%, respectively.
Conclusion: The assays showed excellent concordance with one another, and with a high kappa statistic. The
ELISA kits demonstrated robust diagnostic performance compared to the IB/WB assays. These findings support
the assays’ utility in clinical diagnosis and research in MENA populations.
1. Background
Herpes simplex virus type 1 (HSV-1) is one of the most prevalent
(mostly asymptomatic) infections worldwide [1,2]. Infections with
HSV-1 are associated with oral, ocular, cutaneous, and central nervous
system manifestations, and can result in mild to severe morbidities such
as gingivostomatitis, neonatal herpes, corneal blindness, meningitis,
and encephalitis [3,4]. Although HSV-1 infection is commonly asso-
ciated with orolabial herpes, evidence indicates a growing role for HSV-
1 as a sexually transmitted infection (STI) and as a cause of genital
herpes, even surpassing the role of HSV-2 for incident genital herpes in
some settings [5–7].
The World Health Organization and other global partners have
embarked on multiple activities to accelerate the global roadmap for
STI vaccine development with a focus on an HSV vaccine [8,9]. In
particular, a business case for HSV vaccines is being developed fac-
toring global public health need, vaccines’ potential impact, pathways
of HSV vaccine implementation, anticipated cost-effectiveness, and
return on investment [8]. To advance this global effort, it is essential to
quantify infection levels for both HSV-1 and HSV-2 infections. There-
fore, there is a need to have valid, reliable, and affordable diagnostic
assays for the detection of HSV-1 antibodies among different global
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populations.
The biologic and antigenic distinction between HSV-1 and HSV-2
was first described in the 1960s [10,11]. Although the viruses share
83% of their genome and more than 85% of their protein profile, they
have a prominent antigenic difference in their envelope glycoprotein G
expressed on the surface of the virion, glycoprotein G-1 (gG-1) and G-2
(gG-2), respectively [12]. Epitope mapping studies have shown that
despite amino acid sequence similarities between gG from HSV-1 and
HSV-2, functional antibodies against HSV-1 epitopes do not recognize
gG from HSV-2 [13]. It has been also suggested that glycoprotein gC
from HSV-1 may also be antigenically distinct from the gC of HSV-2
[14].
The number of type-specific commercial enzyme-linked im-
munosorbent assays (ELISA) and immunoblot (IB)/Western blot (WB)
diagnostic assays for the detection of HSV-1 antibodies has increased
over the years [15–19]. While these assays are a mainstay of clinical
diagnosis and scientific research, their performance characteristics can
vary among different global populations [20,21]. To our knowledge, no
study has investigated the performance of such commercially-available
diagnostic assays in the detection of HSV-1 antibodies in Middle East
and North Africa (MENA) populations.
2. Objectives
With a large proportion of the population coming from other MENA
countries, Qatar provides an opportune setting for comparing and
evaluating different type-specific HSV-1 antibody diagnostic assays
among MENA populations. Our main objective was to compare the
performance of four commonly-used and commercially-available assays
in detecting HSV-1 antibodies in a composite population derived from
MENA countries. Specifically, we investigated and compared the con-
cordance of HerpeSelect® 1 ELISA, Euroimmun Anti-HSV-1 (gC1) ELISA
(IgG), HerpeSelect® 1 and 2 Immunoblot IgG, and Euroimmun Anti-
HSV-1/HSV-2 gG2 Euroline-WB (IgG/IgM). Informed by prior studies
[17,18,22], our secondary objective was to assess the diagnostic char-
acteristics of the two ELISA kits with respect to the two IB/WB assays,




Blood specimens were collected from volunteer men blood donors
attending Hamad Medical Corporation, the main healthcare provider in
Doha, Qatar, between June 2013 and 2016. The blood specimens were
originally collected for other studies [23–28]. A total of 4525 blood
specimens were eligible for this study. The sample was comprised of
Qataris and MENA expatriates aged ≥18 years old.
Informed by prior work [17,29], a sample size of 200 was estimated
to be necessary to ensure narrow confidence interval for the Cohen’s
kappa statistic. Twenty specimens were randomly selected from each of
10 MENA populations resulting in a total sample of 200. These 10
MENA populations comprised subjects from Egypt, Iran, Jordan, Le-
banon, Pakistan, Palestine, Qatar, Sudan, Syria, and Yemen. The re-
search work was approved by the ethics boards and research commit-
tees at Hamad Medical Corporation, Qatar University, and Weill Cornell
Medicine-Qatar.
3.2. Detection of anti-HSV-1 IgG
3.2.1. ELISA
Sera were tested for the presence of anti-HSV-1 antibodies using two
commercial ELISA kits: HerpeSelect® 1 ELISA (Cat. No. EL0910G-5,
Focus Diagnostics, USA) and Euroimmun Anti-HSV-1 (gC1) ELISA (IgG)
kit (Cat. No. EI 2531–2 G, Euroimmun, Germany). The HerpeSelect® 1
ELISA kit offered qualitative measurements for HSV-1 IgG antibodies
using purified recombinant gG1 antigen [30]. The Euroimmun ELISA
kit was a semi-quantitative assay that used affinity chromatography
purified-gC1 antigen to detect the presence of HSV-1 antibodies [31].
Both tests were carried out manually according to the manu-
facturers’ instructions, except for the washing step, which was done
automatically. The color intensity was measured using a spectro-
photometer to read the optical density (OD) at 450 nm; an index value
was then obtained by dividing the OD by the mean absorbance of the kit
control sera. For HerpeSelect® 1 ELISA, sera with OD index values<
0.90 were considered anti-HSV-1 negative, values> 1.10 were con-
sidered anti-HSV-1 positive, and values ranging between 0.90 and 1.10
were considered anti-HSV-1 equivocal [30]. For Euroimmun Anti-HSV-
1 (gC1) ELISA, sera with OD index values< 0.80 were considered anti-
HSV-1 negative, values ≥1.10 were considered anti-HSV-1 positive,
and values ranging between 0.80 and 1.10 were considered anti-HSV-1
equivocal [30–32].
3.2.2. IB/WB
ELISA tests may have cutoffs that maximize sensitivity at the pos-
sible expense of specificity. We compared the ELISA kits against two
assays that utilize a different format: 1) HerpeSelect® 1 and 2
Immunoblot IgG (Cat. No. IB0900G, Focus Diagnostic, USA) and 2)
Euroimmun Anti-HSV-1/HSV-2 gG2 Euroline-WB (IgG/IgM) (Cat. No.
DY 2531-1G, Euroimmun, Germany). HerpeSelect® IB test strips were
striped with purified type-specific proteins: HSV-1 gG-1 and HSV-2
gG2, and a common protein mixture [33]. Euroline-WB test strips
contained antigenic extracts of HSV-1 that were electrophoretically
separated, then transferred to paper strips [34].
The two IB/WB assays were performed and interpreted according to
the manufacturers’ instructions. The HerpeSelect® IB is designed to
detect anti-HSV-1 and anti-HSV-2 antibodies. The kit strips contain four
antigen bands: an anti-human serum control band, a herpes common
antigen band (a blend of HSV-1 and HSV-2 native virus antigens), and
recombinant antigen bands for gG-1 (HSV-1) and gG-2 (HSV-2). Each
assay run must, at a minimum, include one antigen strip reacted with a
positive control serum, and one antigen strip reacted with the negative
control serum (provided by the kit). The gG-1 and gG-2 bands on the
positive control are at a low positive “cut-off” staining intensity to
provide a reading comparison. For the test to be considered valid, the
anti-human band must be clearly visualized. In addition, the positive
control serum must react with all of the four bands on the strip, while
the negative control must react with, and only with, the anti-human
serum control band.
Reading of the strips that were valid by the above definition was
done visually by comparing the intensity of the gG-1 and gG-2 bands
relative to the gG-1 and gG-2 bands on the positive control strip. If the
band is as dark or darker than the respective positive control band, then
the band in question is reactive (positive). In contrast, if the band is
lighter than the reading control band, then the band is unreactive
(negative). The overall reactivity of bands is then used to interpret the
results as per a table provided by the manufacturer [33]. For instance,
to be considered positive for anti-HSV-1, the specimen must provide
positive reactions with the anti-human serum, HSV common antigen,
and gG-1 bands. A valid negative specimen for anti-HSV-2 will have
anti-human and HSV type common bands but no band for gG-1. An
equivocal test result is defined as reactive for anti-human serum and
HSV common antigen bands, but negative for gG-1 and gG-2 bands.
On the other hand, results from Euroline-WB were interpreted
qualitatively using a scanner with a EurolineScan software [34]. The
EUROLineScan software is used to scan and digitally evaluate the strips
according to the presence and intensity of recognizable bands on the
blot strips. The EUROLineScan is able to measure band intensities, and
according to the number of units each band produces, it is categorized
into either positive, negative, or equivocal. Negative results were ≤12
units, equivocal 13–20 units, and positive results correlated with ≥20




Results were cross-tabulated for one-to-one comparisons between
the four assays. Equivocal and borderline results were excluded from
the analysis. Four concordance measures were estimated: positive
percent agreement, negative percent agreement, overall percent
agreement, and Cohen’s kappa statistic. Using either HerpeSelect® IB or
Euroline-WB, separately, as the reference standard, sensitivity, specifi-
city, positive predictive value, and negative predictive value were cal-
culated to assess the performance of the two ELISA kits. Level of sig-
nificance was set at 5%, and a 95% confidence interval (CI) was
reported for each measure. All measures were estimated using Microsoft
Excel 2016.
The Cohen’s kappa is a robust statistic that measures the level of
agreement (beyond chance) between two tests [35]. It ranges between 0
and 1. Informed by the literature, Cohen’s kappa values greater than
0.75 represent excellent agreement, values between 0.40 and 0.75 re-
present fair to good agreement, and values below 0.40 represent poor
agreement [35].
4. Results
Fig. 1 shows the cross-tabulations for all six comparisons between
the four assays. Of the 200 MENA blood specimens tested, 171 (85.5%,
95% CI: 79.8–90.1%) were positive for HSV-1 antibodies by HerpeSe-
lect® 1 ELISA, 158 (79.0%; 95% CI: 72.7–84.4%) by Euroimmun ELISA,
and 163 (81.5%; 95% CI: 75.4–86.6%) by Euroline-WB. Due to in-
sufficient sera, three specimens were not tested using HerpeSelect® IB.
As such, of the 197 specimens tested, 162 (82.2%; 95% CI: 76.2–87.3%)
were positive for HSV-1 antibodies by HerpeSelect® IB. No specimen
was equivocal using HerpeSelect® 1 ELISA, while seven specimens were
equivocal using Euroimmun ELISA. Six specimens were equivocal using
HerpeSelect® IB, while eight specimens were equivocal using Euroline-
WB.
There were 177 specimens that had no equivocal results on any
diagnostic test. Among these, 21 (11.9%) were negative and 147
(83.1%) were positive for HSV-1 antibodies in all diagnostic tests used.
Only 4 (2.3%) specimens were positive for HSV-1 antibodies in only one
of the four diagnostic tests while 5 (2.8%) specimens were positive for
HSV-1 antibodies in different combinations of the diagnostic tests.
Fig. 2 reports the concordance assessment measures between the
four diagnostic assays. Positive percent agreement ranged between
95.7% (95% CI: 91.4–98.3%) and 100.0% (95% CI: 97.8–100.0%).
Fig. 1. Cross-tabulated results of 200 specimens tested for HSV-1 antibodies by HerpeSelect® ELISA, Euroimmun ELISA, HerpeSelect® IB, and Euroline-WB assays.
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Negative percent agreement ranged between 86.2% (95% CI:
68.3–96.1%) and 96.6% (95% CI: 82.2–99.9%). Overall percent
agreement ranged between 95.7% (95% CI: 91.7–97.8%) and 99.4%
(95% CI: 97.0–99.9%).
Specifically, the two ELISA kits had a positive percent agreement of
95.7% (95% CI: 91.4–98.3%), a negative percent agreement of 96.6%
(95% CI: 82.2–99.9%), and an overall percent agreement of 95.9%
(95% CI: 92.0–97.9%). The two IB/WB assays had a positive percent
agreement of 100.0% (95% CI: 97.7–100.0%), a negative percent
agreement of 96.2% (95% CI: 80.4–99.9%), and an overall percent
agreement of 99.4% (95% CI: 97.0–99.9%).
The Cohen’s kappa statistic for all six comparisons was ≥0.75 (p-
value<0.001 in all comparisons), indicating excellent agreement [35].
It ranged between 0.84 (95% CI: 0.73–0.95) for the comparison be-
tween Euroimmun ELISA and HerpeSelect® IB and 0.98 (95% CI:
0.93–1.00) for the comparison between HerpeSelect® IB and Euroline-
WB. The Cohen’s kappa statistic for the comparison between the two
ELISA kits was estimated at 0.85 (95% CI: 0.75–0.95).
Fig. 3 shows the four diagnostic and performance assessments for
HerpeSelect® ELISA and Euroimmun ELISA kits in detecting HSV-1
antibodies with respect to the reference IB/WB assays. Overall con-
cordance for all four assessments was estimated at> 95%. Sensitivities
and specificities for all comparisons were estimated at> 96% and>
86%, respectively. Positive and negative predictive values were esti-
mated at> 97% and>83%, respectively.
Against HerpeSelect® IB, HerpeSelect® ELISA detected 162/162 anti-
HSV-1 positive specimens, resulting in a sensitivity of 100.0% (95% CI:
97.8–100.0%). Specificity was 86.2% (95% CI: 68.3–96.1%), while the
positive and negative predictive values were 97.6% (95% CI:
94.0–99.1%) and 100.0% (95% CI 86.7–100.0%), respectively.
Euroimmun ELISA detected 150/155 anti-HSV-1 positive specimens,
resulting in a sensitivity of 96.8% (95% CI: 92.6–98.9%). Specificity
was 89.7% (95% CI: 77.7–97.8%), while the positive and negative
predictive values were 98.0% (95% CI: 94.4–99.3%) and 83.9% (95%
CI 67.4–92.9%), respectively.
Against Euroline-WB, HerpeSelect® ELISA detected 162/163 anti-
HSV-1 positive specimens, resulting in a sensitivity of 99.4% (95% CI:
96.6–100.0%). Specificity was 89.7% (95% CI: 72.7–97.8%), while the
positive and negative predictive values were 98.2% (95% CI:
94.8–99.4%) and 96.3% (95% CI: 81.7–99.3%), respectively.
Euroimmun ELISA detected 152/157 anti-HSV-1 positive specimens,
resulting in a sensitivity of 96.8% (95% CI: 92.7–99.0%). Specificity
was 93.1% (95% CI: 77.2–99.2%), while the positive and negative
predictive values were 98.7% (95% CI: 95.4–99.6%) and 84.4% (95%
CI: 68.3–93.1%), respectively.
5. Discussion
To our knowledge, this is the first examination of the performance
of two commercial ELISA and two commercial IB/WB assays in de-
tecting HSV-1 antibodies in a MENA population. Serological testing
among this population identified high prevalence of positive HSV-1 sera
using HerpeSelect® 1 ELISA (86%), Euroimmun ELISA (79%), Euroline-
WB (82%), and HerpeSelect® IB (82%). However, our results have also
identified several sera as equivocal by Euroline-WB and HerpeSelect IB.
These borderline results reflect the presence of antibodies to HSV
common antigens while simultaneously the absence of glycoprotein gG-
1. Without the visible type specific band, the assay in these cases is not
Fig. 2. Concordance assessment between the results of 200 specimens tested for HSV-1 antibodies by HerpeSelect® ELISA, Euroimmun ELISA, HerpeSelect® IB, and
Euroline-WB assays.
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able to distinguish the type of HSV [36]. These results may be due to
early seroconversion in which type common antibodies may appear
before those to type specific antigens, but this phenomenon has not
been specifically proven for assays, only for Western blot [37].
All assays showed excellent positive, negative, and overall con-
cordance with one another. In the six comparisons between these four
assays, the positive percent agreement was>95%, the negative per-
cent agreement was> 86%, and the overall percent agreement was>
95%. The Cohen’s kappa statistic was also high in all comparisons
(> 0.84). These results support the comparable performance and utility
of using any of these assays to clinically diagnose exposure to this in-
fection, and to assess HSV-1 seroprevalence in MENA populations.
We further found that the two ELISA kits demonstrated robust di-
agnostic performance when compared to each of the IB/WB assays as
the reference assays. In all four comparisons, the sensitivity was> 96%
and the specificity was> 86%. The positive and negative predictive
values were also high at> 97% and>83%, respectively. The sensi-
tivities, specificities, and positive predictive values were also similar for
both ELISA kits, though a slight difference was identified for the ne-
gative predictive value. The latter was higher for HerpeSelect® ELISA
compared to Euroimmun ELISA. These results further support the utility
of these two ELISA kits in clinically diagnosing exposure to this virus
and measuring HSV-1 seroprevalence, particularly in MENA popula-
tions.
There is evidence for variation in the sensitivity and specificity of
HSV-1 assays by population [20,30,38]. Data from the United States of
America suggests that HerpeSelect® ELISA has less than optimal sensi-
tivity and may miss> 20% of seropositive cases compared to WB
[39–42]. Our results here and our earlier HSV-1 seroprevalence study
[27], however, suggests that this may not be the case for MENA po-
pulations—we measured very high HSV-1 seroprevalence in several
MENA populations that was> 90%. Different levels of exposure and re-
challenge to this infection and different immune activation levels, as
well as global diversity within and between HSV-1 and HSV-2 glyco-
proteins [43], may explain some of the observed differences in sensi-
tivity by population. Consequently, this provides an opportunity for
further research to conduct similar comparison studies in other global
populations, and to compare the similarities and variations in the re-
sults from one population to another.
The similar outcomes of these assays and their concordance suggest
that any of them could be used for clinical diagnosis and scientific re-
search. However, logistical factors may favor the use of one as opposed
to another in a specific setting—the choice of assay may depend on the
kit’s availability, its costs, and laboratory infrastructure and demands
for its use. For example, the total incubation duration for the
Euroimmun ELISA kit is 75min [31], in comparison to 100min for the
HerpeSelect® ELISA kit [30], which could be an important factor if a
large number of specimens need to be tested in a specific laboratory.
Meanwhile, Focus has automated platforms for their ELISA that can
reduce the hands-on time in processing the samples.
There are limitations to this study. Our sample included blood
specimens only from men, as we used existing sera that was collected
from men. There were three specimens (two were positive by ELISA and
confirmed positive by Euroline-WB) that were not tested using
HerpeSelect® IB due to insufficient sera. Measures of agreement be-
tween assays, such as Cohen’s kappa statistic, can depend on the true
seroprevalence of infection [44], but our sample may not be re-
presentative for the true seroprevalence in the population. However,
the observed seroprevalence in this sample was similar to that observed
in MENA populations [27,45], and we employed a sampling strategy
that enhances the representativeness of this sample of diverse MENA
populations (20 random specimens selected per nationality for 10 na-
tionalities). We treated HerpeSelect® IB and Euroline-WB as reference
standards for the purpose of comparison, based on their IB/WB biolo-
gical format and because we could not use (for logistical reasons) the
University of Washington’s WB, considered widely as the reference gold
standard for HSV serology [15]. The use of HerpeSelect® IB and Euro-
line-WB for diagnosis and confirmation has been reported in the lit-
erature [15–17], but, ideally, larger studies will affirm their accuracy
for HSV-1 detection.
In conclusion, we conducted a comparison study of four commonly-
used commercial assays in detecting HSV-1 antibodies in a MENA po-
pulation. All assays showed excellent positive, negative, and overall
concordance with one another, and with a high Cohen’s kappa statistic.
Fig. 3. Performance assessment in detecting HSV-1 antibodies for HerpeSelect® ELISA and Euroimmun ELISA assays with respect to each of the two reference
standards of HerpeSelect® IB, and Euroline-WB assays.
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The two ELISA kits demonstrated robust and similar diagnostic char-
acteristics when compared to each of the IB/WB assays. These findings
support the utility of using these assays in clinical diagnosis and sci-
entific research in MENA populations.
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